Alumis is a Biotech company based in South San Francisco. It has raised $529M in total funding. Latest round: Series C.
Alumis funding overview
Alumis is a Biotech company based in South San Francisco. Alumis has raised $529M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series C announced in March 2024. The round record for Alumis runs through 2024; nothing later has been disclosed. Investors on record include Foresite Capital, Samsara BioCapital, venBio Partners, Lilly Asia Ventures, Cormorant Asset Management, SR One and 7 others. 13 distinct backers are named across the disclosed rounds.
Alumis at a glance
Total raised
$529M
Latest round
Series C
Latest round date
March 2024
Industry
Biotech
Headquarters
South San Francisco
Notable investors
Foresite Capital, Samsara BioCapital, venBio Partners, Lilly Asia Ventures, Cormorant Asset Management, SR One, Nextech, Ally Bridge Group
Frequently asked about Alumis funding
How much has Alumis raised?
Alumis has raised $529M in total disclosed funding across the rounds on record.
Who has invested in Alumis?
Foresite Capital, Samsara BioCapital, venBio Partners, Lilly Asia Ventures, Cormorant Asset Management, SR One are named among the investors backing Alumis.
What was the latest Alumis funding round?
The most recent disclosed round is a Series C, announced in March 2024.
Where is Alumis based?
Alumis is based in South San Francisco.
What sector does Alumis operate in?
Alumis is tracked under Biotech from South San Francisco, with $529M in disclosed funding.
When did Alumis last raise?
The last disclosed Alumis round closed in March 2024 at Series C.
We update the Alumis record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related Biotech companies in South San Francisco and their backers are listed below.
